Participation to the Small New World 2.0 meeting
We participated to the Small New World 2.0 meeting in Graz, Austria September 12th, 2023, Vienna, Austria We participated to the
RPTEC/TERT1 relevant kidney-on-a-chip model
Collaboration with Nortis to establish human kidney-on-a-chip model August 4th, 2023. Vienna, Austria Our telomerized Human Renal Proximal Tubular Epithelial cells (RPTEC/TERT1) were used in collaboration with
Participation in the CHANGE project
We are proud to announce our participation in the CHANGE project May 4th, 2023, Vienna, Austria The CHANGE project focuses on
Wharton’s jelly MSC-EVs
Recent publication showcasing our telomerized Wharton's jelly-MSCs as EV-cell factories April 4th, 2023, Vienna, AustriaOur telomerized Wharton's jelly-derived MSCs (WJ-MSC/TERT273)
The LifeSaver project film
The LifeSaver project film November 30, 2022, Vienna, Austria Evercyte is a proud participant in the LifeSaver Project
Placenta-derived mesenchymal stem cells
New mesenchymal stromal cell lines from placental tissue for production of exosomes are now available! December 1st, 2021, Vienna, Austria Mesenchymal
Participation in the LIFESAVER project
We are proud to announce our participation in the LIVESAVER project November 25, 2021, Vienna, Austria The LIFESAVER project addresses the
Recombinant extracellular vesicles
Engineering of CD81 on extracellular vesicles to target specific cell surface proteins. September 17, 2021, Vienna, AustriaWe have developed a platform technology
MDimune and Evercyte form partnership for developing tumor-targeting EVs
MDimune and Evercyte form partnership for developing tumor-targeting EVs April 1, 2021, Seoul, Korea and Vienna, Austria MDimune Inc. and Evercyte GmbH announced a
Knock-out of CD46 in RPTEC/TERT1 cells
Knock-out of CD46 in RPTEC/TERT1 cells Application: gene editing of human telomerized cells with CRISPR/Cas9 knock-out of CD46 in RPTEC/TERT1 cells using CRISPR